The Directory of Pharma Companies and News


Basilea logo
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website
Category: Pharmaco
Category: Pharmaco

Basilea News

-0001-11-30Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553
-0001-11-30Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor
-0001-11-30Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Share...
-0001-11-30Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID
-0001-11-30Basilea in-licenses targeted cancer therapy
-0001-11-30Basilea reports U.S. FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis
-0001-11-30Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera® in Europe
-0001-11-30Basilea announces that FDA's Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatm...
-0001-11-30Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia
-0001-11-30Basilea announces launch of antibiotic Zevtera® (ceftobiprole medocaril) in Germany
-0001-11-30Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis a...
-0001-11-30Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections
-0001-11-30Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections
-0001-11-30Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA® and Zevtera®
-0001-11-30Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor
-0001-11-30Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC p...
-0001-11-30Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
-0001-11-30Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa...
-0001-11-30Basilea announces filing of registration statement for a proposed offering in the United States
-0001-11-30Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis ...
-0001-11-30Basilea announces that European Commission maintained isavuconazole's orphan drug status
-0001-11-30Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
-0001-11-30Basilea launches a senior convertible bond issue
-0001-11-30Basilea successfully places CHF 200 million senior convertible bonds
-0001-11-30Final allocations of Basilea CHF 200 million senior convertible bonds
-0001-11-30Basilea provides clinical program updates
-0001-11-30Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
-0001-11-30GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
-0001-11-30Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
-0001-11-30Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
-0001-11-30Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
-0001-11-30Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label st...
-0001-11-30Basilea issues agenda for Annual General Meeting of Shareholders
-0001-11-30Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and In...
-0001-11-30Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
-0001-11-30Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting
-0001-11-30Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
-0001-11-30Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
-0001-11-30Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
-0001-11-30Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
-0001-11-30Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
-0001-11-30Basilea names new member of its Extended Management Committee
-0001-11-30Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
-0001-11-30Basilea's antifungal Cresemba® (isavuconazole) launched in France
-0001-11-30Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the ...
-0001-11-30Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
-0001-11-30Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zev...
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.